Department of Radiology and Radiological Sciences Presents the Annual

Sandler Lecture in Nuclear Medicine and Molecular Imaging

"Radioiodine Theranostics for Differentiated Thyroid Cancer"

featuring

Anca M. Avram, MD

Anca M. Avram, MD

Professor of Radiology
Director, Nuclear Medicine Therapy Clinic
University of Michigan
Ann Arbor, Michigan

 

 

TBD 2020 | Noon - 1 p.m.

MCN CCC-1111

Watch the Presentation Here

---------------------------------------------------------------

This grand rounds lecture is designed for faculty, residents, staff and medical students.

Learning objectives of this presentation include:

  • Apply risk-stratification criteria for determining the post-operative management of thyroid cancer patients 
  • Integrate information obtained from diagnostic radioiodine scintigraphy with SPECT/CT into risk-stratification and staging of thyroid cancer 
  • Identify the patterns of regional and distant metastases on diagnostic radioiodine SPECT/CT and determine the prognostic significance of findings

+++

Anca M. Avram, MD, is Professor of Radiology at the University of Michigan, in Ann Arbor where she currently serves as Director of the Nuclear Medicine Therapy Program. After post-graduate training in Internal Medicine, she pursued advanced specialty training in Endocrinology, Metabolism and Diabetes, and in Nuclear Medicine, both completed at the University of Michigan. Dr. Avram is certified by the American Board of Internal Medicine, the American Board of Endocrinology & Metabolism, and the American Board of Nuclear Medicine.  Dr. Avram is an internationally recognized expert in the field of thyroid cancer, has authored 70 peer-reviewed scientific manuscripts, 50 abstract presentations and 10 book chapters. Her clinical interests include radioactive iodine treatment for hyperthyroidism, thyroid cancer and radioimmunotherapy for lymphoma. Dr. Avram’s research interests focus on the role of diagnostic radioiodine imaging for guiding 131-I treatment for thyroid cancer (radiotheranostics), and clinical dosimetry protocols for metastatic thyroid cancer.